No Data
No Data
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Bristol-Myers Squibb (NYSE:BMY) Increases 4.7% This Week, Taking One-year Gains to 24%
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
104476495 : h
104476495 : h
104247826 :
Malik ritduan : ok
大马周瑜 : ok
View more comments...